One of the most successful was adalimumab, discovered by Cambridge Antibody Technology as D2E7 and developed and marketed by Abbott Laboratories.
Un dos máis exitosos foi adalimumab, descuberto por Cambridge Antibody Technology como D2E7 e desenvolvido e comercializado por Abbott Laboratories.